Top

Published in:

01-07-2019 | Soft Tissue Sarcoma | Clinical Study

Nomograms for predicting the overall and cause-specific survival in patients with malignant peripheral nerve sheath tumor: a population-based study

Authors: Penghui Yan, Runzhi Huang, Peng Hu, Fengsen Liu, Xiaolong Zhu, Peizhu Hu, Huabin Yin, Jie Zhang, Tong Meng, Zongqiang Huang

Published in: Journal of Neuro-Oncology | Issue 3/2019

Abstract

Background

Malignant peripheral nerve sheath tumor (MPNST) is extremely rare in soft tissue sarcoma, with a high rate of recurrence and metastasis. Due to its rarity, the epidemiological features and prognostic factors are still uncertain. Moreover, nomograms for patients with MPNST have not been constructed and validated until now.

Patients and methods

Patients diagnosed with MPNST between 1973 and 2014 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Survival analysis, machine learning and Lasso regression were used to identify the prognostic factors for overall survival (OS) and cause-specific survival (CSS). Significant prognostic factors were integrated to construct nomograms and then the nomograms were validated externally with a separate cohort from our own institution.

Results

A total of 689 patients were included in the training set and 42 patients in the validation set. Multivariate analysis suggested that age, histology, historic stage and chemotherapy were independent prognostic factors for OS and primary site, surgery, historic stage and chemotherapy for CSS. The nomograms based on multivariate models were developed and validated for predicting 3- and 5-year OS and CSS, with a C-index of 0.686 and 0.707, respectively. In the external validation set, the C-index was 0.700 for OS and 0.722 for CSS.

Conclusion

ICD-O-3 histology, historic stage and chemotherapy were independent prognostic factors for OS and primary site, surgery, historic stage and chemotherapy for CSS. The constructed nomograms could provide individual prediction for MPNST patients and assist oncologists in making accurate survival evaluation.

Available only for authorised users

Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res 62:1573–1577PubMed

Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, Sotti G, Treuner J (2005) Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 23:8422–8430. https://doi.org/10.1200/JCO.2005.01.4886 CrossRefPubMed

Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S, Gronchi A (2006) Malignant peripheral nerve sheath tumors - Prognostic factors and survival in a series of patients treated at a single institution. Cancer-Am Cancer Soc 107:1065–1074. https://doi.org/10.1002/cncr.22098 CrossRef

Fuchs B, Spinner RJ, Rock MG (2005) Malignant peripheral nerve sheath tumors: an update. J Surg Orthop Adv 14:168–174PubMed

Okada K, Hasegawa T, Tajino T, Hotta T, Yanagisawa M, Osanai T, Nishida J, Seki K, Itoi E (2007) Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol 14:597–604. https://doi.org/10.1245/s10434-006-9053-5 CrossRefPubMed

Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN (2008) Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations. J Surg Oncol 97:340–349. https://doi.org/10.1002/jso.20971 CrossRefPubMed

Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, Isambert N, Thariat J, Linassier C, Bertucci F, Bay JO, Bellesoeur A, Penel N, Le Guellec S, Filleron T, Chevreau C (2016) Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer 56:77–84. https://doi.org/10.1016/j.ejca.2015.12.015 CrossRefPubMed

Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D (2009) Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 249:1014–1022. https://doi.org/10.1097/SLA.0b013e3181a77e9a CrossRefPubMed

Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, Wasif N (2012) Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol 19:878–885. https://doi.org/10.1245/s10434-011-1978-7 CrossRefPubMed

10.

Fan Q, Yang J, Wang G (2014) Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor. Clin Transl Oncol 16:191–199. https://doi.org/10.1007/s12094-013-1061-x CrossRefPubMed

11.

Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, Wang Z, Zhu Z, Deng Q, Xiong X, Shao W, Shi X, He J (2015) Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol 33:861–869. https://doi.org/10.1200/JCO.2014.56.6661 CrossRefPubMed

12.

Deng QL, Dong S, Wang L, Zhang CY, Ying HF, Li ZS, Shen XH, Guo YB, Meng ZQ, Yu JM, Chen QW (2017) Development and validation of a nomogram for predicting survival in patients with advanced pancreatic ductal adenocarcinoma. Sci Rep 7:11524. https://doi.org/10.1038/s41598-017-11227-8 CrossRefPubMedPubMedCentral

13.

Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, Wan X, Liu G, Wu D, Shi L, Lau W, Wu M, Shen F (2013) Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol 31:1188–1195. https://doi.org/10.1200/JCO.2012.41.5984 CrossRefPubMed

14.

Wang ZX, Qiu MZ, Jiang YM, Zhou ZW, Li GX, Xu RH (2017) Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer. J Cancer 8:950–958. https://doi.org/10.7150/jca.17370 CrossRefPubMedPubMedCentral

15.

Zhang ZY, Luo QF, Yin XW, Dai ZL, Basnet S, Ge HY (2016) Nomograms to predict survival after colorectal cancer resection without preoperative therapy. BMC Cancer 16:658. https://doi.org/10.1186/s12885-016-2684-4 CrossRefPubMedPubMedCentral

16.

Zhang ZY, Gao W, Luo QF, Yin XW, Basnet S, Dai ZL, Ge HY (2016) A nomogram improves AJCC stages for colorectal cancers by introducing CEA, modified lymph node ratio and negative lymph node count. Sci Rep 6:39028. https://doi.org/10.1038/srep39028 CrossRefPubMedPubMedCentral

17.

Cronin KA, Ries LA, Edwards BKJC (2014) The surveillance, epidemiology, and end results (SEER) program of the National Cancer Institute. Oral Oncol 120(Suppl 23): 3755.

18.

Coccia PF, Pappo AS, Beaupin L, Borges VF, Borinstein SC, Chugh R, Dinner S, Folbrecht J, Frazier AL, Goldsby R, Gubin A, Hayashi R, Huang MS, Link MP, Livingston JA, Matloub Y, Millard F, Oeffinger KC, Puccetti D, Reed D, Robinson S, Rosenberg AR, Sanft T, Spraker-Perlman HL, von Mehren M, Wechsler DS, Whelan KF, Yeager N, Gurski LA, Shead DA (2018) Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16:66–97. https://doi.org/10.6004/jnccn.2018.0001 CrossRef

19.

Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer-Am Cancer Soc 57:2006–2021

20.

Eilber FC, Brennan MF, Eilber FR, Dry SM, Singer S, Kattan MW (2004) Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer-Am Cancer Soc 101:2270–2275. https://doi.org/10.1002/cncr.20570 CrossRef

21.

Arshi A, Tajudeen BA, John MSJOO (2015) Malignant peripheral nerve sheath tumors of the head and neck: demographics, clinicopathologic features, management, and treatment outcomes. Oral Oncol 51:1088–1094CrossRefPubMed

22.

Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ (1995) Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 221:185–195CrossRefPubMedPubMedCentral

23.

Brooks JS, Freeman M, Enterline HT (1985) Malignant "Triton" tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer-Am Cancer Soc 55:2543–2549

24.

Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PGJC (2006) Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. 107:1065–1074

25.

Hruban RH, Shiu MH, Senie RT, Woodruff JM (1990) Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer-Am Cancer Soc 66:1253–1265

26.

Raney B, Schnaufer L, Ziegler M, Chatten J, Littman P, Jarrett PJC (1987) Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia 1958–1984(59):1–5

Title: Nomograms for predicting the overall and cause-specific survival in patients with malignant peripheral nerve sheath tumor: a population-based study
Authors: Penghui Yan
Runzhi Huang
Peng Hu
Fengsen Liu
Xiaolong Zhu
Peizhu Hu
Huabin Yin
Jie Zhang
Tong Meng
Zongqiang Huang
Publication date: 01-07-2019
Publisher: Springer US
Keywords: Soft Tissue Sarcoma
Cytostatic Therapy
Published in: Journal of Neuro-Oncology / Issue 3/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03181-4

At a glance: The STEP trials

Springer Medicine

Nomograms for predicting the overall and cause-specific survival in patients with malignant peripheral nerve sheath tumor: a population-based study

Abstract

Background

Patients and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells

Comparative analysis of intracranial meningiomas in patients younger than 40 years

Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

Rescue bevacizumab following symptomatic pseudoprogression of a tectal glioma post-radiotherapy: a case report and review of the literature

Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres